AU2005692A - Method for designing cancer treatment regimens and methods and pharmaceutical compositions for the treatment of cancer - Google Patents
Method for designing cancer treatment regimens and methods and pharmaceutical compositions for the treatment of cancerInfo
- Publication number
- AU2005692A AU2005692A AU20056/92A AU2005692A AU2005692A AU 2005692 A AU2005692 A AU 2005692A AU 20056/92 A AU20056/92 A AU 20056/92A AU 2005692 A AU2005692 A AU 2005692A AU 2005692 A AU2005692 A AU 2005692A
- Authority
- AU
- Australia
- Prior art keywords
- cancer
- treatment
- methods
- pharmaceutical compositions
- designing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title 2
- 201000011510 cancer Diseases 0.000 title 2
- 238000000034 method Methods 0.000 title 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
- 238000011269 treatment regimen Methods 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69692391A | 1991-05-08 | 1991-05-08 | |
| US696923 | 1991-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2005692A true AU2005692A (en) | 1992-12-21 |
Family
ID=24799069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU20056/92A Abandoned AU2005692A (en) | 1991-05-08 | 1992-05-08 | Method for designing cancer treatment regimens and methods and pharmaceutical compositions for the treatment of cancer |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2005692A (en) |
| WO (1) | WO1992019765A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993014787A1 (en) * | 1992-01-31 | 1993-08-05 | The Trustees Of Columbia University In The City Of New York | Taxol as a radiation sensitizer |
| CA2086874E (en) * | 1992-08-03 | 2000-01-04 | Renzo Mauro Canetta | Methods for administration of taxol |
| GB2269319B (en) * | 1992-08-03 | 1997-04-09 | Bristol Myers Squibb Co | Methods for administration of taxol |
| FR2697752B1 (en) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Antitumor compositions containing taxane derivatives. |
| FR2698871B1 (en) | 1992-12-09 | 1995-02-24 | Rhone Poulenc Rorer Sa | New taxoids, their preparation and the pharmaceutical compositions containing them. |
| US6441026B1 (en) | 1993-11-08 | 2002-08-27 | Aventis Pharma S.A. | Antitumor compositions containing taxane derivatives |
| WO1997001344A2 (en) * | 1995-06-27 | 1997-01-16 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Method of dynamic retardation of cell cycle kinetics to potentiate cell damage |
| US6274576B1 (en) | 1995-06-27 | 2001-08-14 | The Henry Jackson Foundation For The Advancement Of Military Medicine | Method of dynamic retardation of cell cycle kinetics to potentiate cell damage |
| EP1318794A2 (en) | 2000-09-22 | 2003-06-18 | Bristol-Myers Squibb Company | Method for reducing toxicity of combined chemotherapies |
-
1992
- 1992-05-08 AU AU20056/92A patent/AU2005692A/en not_active Abandoned
- 1992-05-08 WO PCT/US1992/003830 patent/WO1992019765A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO1992019765A1 (en) | 1992-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP9902068A3 (en) | Methods and compositions for the diagnosis and treatment of cancer | |
| AU3691793A (en) | Gas well treatment compositions and methods | |
| ZA957483B (en) | Compounds and methods for the treatment of cancer | |
| AU2187992A (en) | Composition and method for disease treatment | |
| AU5606494A (en) | Methods and pharmaceutical compositions for enhanced cardiopulmonary resuscitation | |
| AU6592390A (en) | Method and apparatus for the treatment of cancer | |
| AU3519893A (en) | Antitumor compositions and methods of treatment | |
| AU8044491A (en) | Antitumor compositions and methods of treatment | |
| SK60895A3 (en) | Taxane derivatives and process for their preparation | |
| AU3406893A (en) | Method and composition for the treatment of osteoporosis | |
| AU8192691A (en) | Method of treatment and compositions therefore | |
| IL101410A0 (en) | Formulation for the treatment of cancer | |
| AU2821295A (en) | Compositions and methods for the treatment of tumors | |
| IL101245A0 (en) | Pharmaceutical compositions for the treatment of prostatic cancer | |
| AU2005692A (en) | Method for designing cancer treatment regimens and methods and pharmaceutical compositions for the treatment of cancer | |
| IL115320A0 (en) | Retinoyloxy (substituted) methyl butyrates useful for the treatment of cancer and other proliferative diseases | |
| AU7770991A (en) | Method and composition for the treatment of cancer | |
| AU3973793A (en) | Method of treating cancer | |
| IL106763A0 (en) | Pharmaceutical compositions for treating cancer | |
| GB9112552D0 (en) | Method and composition for the treatment of cancer | |
| GB9007763D0 (en) | Method and composition for the treatment of cancer | |
| GB9123572D0 (en) | Pharmaceutical compositions and methods for the treatment of malignancy | |
| EP0478660A4 (en) | Pharmaceutical compositions and methods for treating inflammation | |
| AU6358994A (en) | Method of cancer treatment | |
| GB9024181D0 (en) | Pharmaceutical compositions and methods for the treatment of malignancy |